“This is different from other standard-of-care therapies for prostate cancer because usually we are inhibiting androgen receptor (AR) activity and here we’re actually stimulating AR,” explained Laura Anne Sena, MD, PhD.
In an interview during the SUO 2023 Annual Meeting, Laura Anne Sena, MD, PhD, explained the technique of bipolar androgen therapy for the treatment of patients with prostate cancer. Sena is an instructor of oncology at Johns Hopkins Medicine.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.